A Jatoi1, P D Steen2, P J Atherton1, D F Moore3, K M Rowland4, N A Le-Lindqwister5, C S Adonizio6, A J Jaslowski7, J Sloan1, C Loprinzi1. 1. Division of Medical Oncology, Mayo Clinic, Rochester. 2. Sanford Health NCORP, Fargo. 3. Wichita Community Clinical Oncology Program, Wichita. 4. Carle Cancer Center CCOP, Urbana. 5. Illinois Oncology Research Assn. CCOP, Peoria. 6. Geisinger Clinic & Medical Center CCOP, Danville. 7. St. Vincent Regional Cancer Center CCOP, Green Bay, USA.
Abstract
BACKGROUND: Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome. PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, incurable patients with this syndrome were assigned creatine (20 g/day load×5 days followed by 2 g/day orally) versus identical placebo. Patients were weighed once a week for 1 month and then monthly. Patients were also assessed over 1 month for appetite and quality of life (validated questionnaires), fist grip strength, body composition (bioelectrical impedance), and adverse events. The primary endpoint was 10% or greater weight gain from baseline during the first month. RESULTS: Within this combined cohort of 263 evaluable patients (134 received creatine and 129 placebo), only 3 gained ≥10% of their baseline weight by 1 month: two creatine-treated and the other placebo-exposed (P = 1.00). Questionnaire data on appetite, quality of life, and activities of daily living showed no statistically significant differences between groups. Similarly, no statistically significant differences between groups were observed for fist-grip strength or body composition. Rates and severity of adverse events were comparable between groups. Finally, a median survival of 230 and 239 days were observed in the creatine and placebo groups, respectively (P = 0.70). CONCLUSION: Creatine, as prescribed in this trial, had no effect on the cancer anorexia/weight loss syndrome.
BACKGROUND: Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome. PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, incurable patients with this syndrome were assigned creatine (20 g/day load×5 days followed by 2 g/day orally) versus identical placebo. Patients were weighed once a week for 1 month and then monthly. Patients were also assessed over 1 month for appetite and quality of life (validated questionnaires), fist grip strength, body composition (bioelectrical impedance), and adverse events. The primary endpoint was 10% or greater weight gain from baseline during the first month. RESULTS: Within this combined cohort of 263 evaluable patients (134 received creatine and 129 placebo), only 3 gained ≥10% of their baseline weight by 1 month: two creatine-treated and the other placebo-exposed (P = 1.00). Questionnaire data on appetite, quality of life, and activities of daily living showed no statistically significant differences between groups. Similarly, no statistically significant differences between groups were observed for fist-grip strength or body composition. Rates and severity of adverse events were comparable between groups. Finally, a median survival of 230 and 239 days were observed in the creatine and placebo groups, respectively (P = 0.70). CONCLUSION: Creatine, as prescribed in this trial, had no effect on the cancer anorexia/weight loss syndrome.
Authors: Aminah Jatoi; Harold E Windschitl; Charles L Loprinzi; Jeff A Sloan; Shaker R Dakhil; James A Mailliard; Sarode Pundaleeka; Carl G Kardinal; Tom R Fitch; James E Krook; Paul J Novotny; Brad Christensen Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Aminah Jatoi; Howard L Ritter; Amylou Dueck; Phuong L Nguyen; Daniel A Nikcevich; Ronnie F Luyun; Bassam I Mattar; Charles L Loprinzi Journal: Lung Cancer Date: 2009-08-08 Impact factor: 5.705
Authors: Sarah Johannsmeyer; Darren G Candow; C Markus Brahms; Deborah Michel; Gordon A Zello Journal: Exp Gerontol Date: 2016-08-11 Impact factor: 4.032
Authors: Darpan I Patel; Angela Gonzalez; Crisann Moon; Monica Serra; Preston Blake Bridges; Daniel Hughes; Geoffrey Clarke; Lisa Kilpela; Rozmin Jiwani; Nicolas Musi Journal: JMIR Res Protoc Date: 2022-04-01